Stocks
Neurotrope Financial Statements (NTRP) |
||||||||||
| Neurotropesmart-lab.ru | % | 2018 | 2019 | 2020 | 2021 | 2022 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 08.03.2019 | 13.03.2020 | 31.12.2020 | 31.12.2021 | 31.12.2022 | 30.09.2023 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 0.000 | 0.000 | 0.807 | 1.65 | 0.630 | 0.523 | |||
| Operating Income, bln rub | -11.1 | -15.5 | -5.70 | -8.48 | -8.75 | -5.93 | ||||
| EBITDA, bln rub | ? | -11.0 | -15.1 | -5.08 | -7.28 | -8.55 | -5.76 | |||
| Net profit, bln rub | ? | -11.0 | -15.1 | -5.20 | -7.38 | -8.69 | -5.88 | |||
| OCF, bln rub | ? | -7.70 | -11.9 | -4.81 | -6.30 | -8.21 | -4.41 | |||
| CAPEX, bln rub | ? | 0.003 | 0.005 | 0.299 | 0.360 | 0.389 | 0.275 | |||
| FCF, bln rub | ? | -7.70 | -11.9 | -5.11 | -6.66 | -8.60 | -4.69 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 11.1 | 15.5 | 5.76 | 9.57 | 8.95 | 6.14 | ||||
| Cost of production, bln rub | 0.000 | 0.000 | 0.592 | 0.560 | 0.350 | 0.313 | ||||
| R&D, bln rub | 4.89 | 4.54 | 0.351 | 0.891 | 0.653 | 0.443 | ||||
| Interest expenses, bln rub | 0.000 | 0.000 | 0.014 | 0.011 | 0.007 | 0.012 | ||||
| Assets, bln rub | 29.5 | 17.9 | 5.70 | 13.8 | 5.70 | 2.84 | ||||
| Net Assets, bln rub | ? | 26.5 | 17.4 | 5.16 | 12.9 | 5.07 | 1.97 | |||
| Debt, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Cash, bln rub | 28.9 | 17.4 | 3.70 | 11.4 | 2.85 | 0.556 | ||||
| Net debt, bln rub | -28.9 | -17.4 | -3.70 | -11.4 | -2.85 | -0.56 | ||||
| Ordinary share price, rub | 30.0 | 19.6 | 67.6 | 36.8 | 8.00 | 0.945 | ||||
| Number of ordinary shares, mln | 8.05 | 13.0 | 0.191 | 0.491 | 0.525 | 0.560 | ||||
| Market cap, bln rub | 242 | 255 | 13 | 18 | 4 | 1 | ||||
| EV, bln rub | ? | 213 | 238 | 9 | 7 | 1 | 0 | |||
| Book value, bln rub | 27 | 17 | 4 | 12 | 4 | 1 | ||||
| EPS, rub | ? | -1.37 | -1.16 | -27.2 | -15.0 | -16.6 | -10.5 | |||
| FCF/share, rub | -0.96 | -0.92 | -26.7 | -13.5 | -16.4 | -8.37 | ||||
| BV/share, rub | 3.29 | 1.34 | 23.0 | 24.3 | 7.52 | 1.30 | ||||
| EBITDA margin, % | ? | -629.0% | -440.7% | -1 357% | -1 102% | |||||
| Net margin, % | ? | -644.0% | -447.1% | -1 379% | -1 124% | |||||
| FCF yield, % | ? | -3.19% | -4.66% | -39.5% | -36.8% | -204.8% | -885.4% | |||
| ROE, % | ? | -41.6% | -86.9% | -100.7% | -57.4% | -171.3% | -297.7% | |||
| ROA, % | ? | -37.4% | -84.6% | -91.2% | -53.4% | -152.4% | -207.1% | |||
| P/E | ? | -21.9 | -16.9 | -2.49 | -2.45 | -0.48 | -0.09 | |||
| P/FCF | -31.4 | -21.5 | -2.53 | -2.72 | -0.49 | -0.11 | ||||
| P/S | ? | 16.0 | 10.9 | 6.66 | 1.01 | |||||
| P/BV | ? | 9.11 | 14.6 | 2.93 | 1.52 | 1.06 | 0.73 | |||
| EV/EBITDA | ? | -19.3 | -15.7 | -1.82 | -0.91 | -0.16 | 0.00 | |||
| Debt/EBITDA | 2.62 | 1.15 | 0.73 | 1.57 | 0.33 | 0.10 | ||||
| R&D/CAPEX, % | 153 345% | 87 091% | 117.6% | 247.5% | 167.9% | 161.3% | ||||
| CAPEX/Revenue, % | 37.0% | 21.8% | 61.7% | 52.5% | ||||||
| Neurotrope shareholders | ||||||||||
